Inducing pluripotency for disease modeling, drug development and craniofacial applications

Bibliography

• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72
   PubMed Web of Science ®Google Scholar
• Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-56
   PubMed Web of Science ®Google Scholar
• Sridharan R, Tchieu J, Mason MJ, et al. Role of the murine reprogramming factors in the induction of pluripotency. Cell 2009;136:364-77
   PubMed Web of Science ®Google Scholar
• Tokuzawa Y, Kaiho E, Maruyama M, et al. Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Mol Cell Biol 2003;23:2699-708
   PubMed Web of Science ®Google Scholar
• Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-17
   PubMed Web of Science ®Google Scholar
• Maherali N, Sridharan R, Xie W, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007;1:55-70
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-6
   PubMed Web of Science ®Google Scholar
• Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008;2:10-12
   PubMed Web of Science ®Google Scholar
• Wang J, Rao S, Chu J, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006;444:364-8
   PubMed Web of Science ®Google Scholar
• Hatano SY, Tada M, Kimura H, et al. Pluripotential competence of cells associated with Nanog activity. Mech Dev 2005;122:67-79
   PubMed Web of Science ®Google Scholar
• Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003;113:643-55
   PubMed Web of Science ®Google Scholar
• Hanna J, Saha K, Pando B, et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 2009;462:595-601
   PubMed Web of Science ®Google Scholar
• Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011;8:376-88
   PubMed Web of Science ®Google Scholar
• Ma T, Xie M, Laurent T, Ding S. Progress in the reprogramming of somatic cells. Circ Res 2013;112:562-74
   Google Scholar
• Lyssiotis CA, Foreman RK, Staerk J, et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci USA 2009;106:8912-17
   PubMed Web of Science ®Google Scholar
• Zhu S, Li W, Zhou H, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010;7:651-5
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Q, Yin X, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res 2011;21:196-204
   PubMed Web of Science ®Google Scholar
• Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013;341:651-4
   PubMed Web of Science ®Google Scholar
• Rajamohan D, Matsa E, Kalra S, et al. Current status of drug screening and disease modelling in human pluripotent stem cells. Bioessays 2013;35:281-98
   PubMed Web of Science ®Google Scholar
• Doevendans PA, Daemen MJ, de Muinck ED, Smits JF. Cardiovascular phenotyping in mice. Cardiovasc Res 1998;39:34-49
   PubMed Web of Science ®Google Scholar
• Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002;420:520-62
   PubMed Web of Science ®Google Scholar
• Bhanushali M, Bagale V, Shirode A, et al. An in-vitro toxicity testing - a reliable alternative to toxicity testing by reduction, replacement and refinement of animals. J Adv Pharm Sci 2010;1:15-31
   Google Scholar
• Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7
   PubMed Web of Science ®Google Scholar
• Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 2009;5:584-95
   PubMed Web of Science ®Google Scholar
• Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 2011;10:915-29
   PubMed Web of Science ®Google Scholar
• Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460:53-9
   PubMed Web of Science ®Google Scholar
• Pedrosa E, Sandler V, Shah A, et al. Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. J Neurogenet 2011;25:88-103
   PubMed Web of Science ®Google Scholar
• Ebert AD, Liang P, Wu JC. Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol 2012;60:408-16
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-68
   PubMed Web of Science ®Google Scholar
• Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009;4:1140-50
   PubMed Web of Science ®Google Scholar
• Jakel RJ, Schneider BL, Svendsen CN. Using human neural stem cells to model neurological disease. Nat Rev Genet 2004;5:136-44
   PubMed Web of Science ®Google Scholar
• Chang T, Zheng W, Tsark W, et al. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 2011;29:2090-3
   PubMed Web of Science ®Google Scholar
• Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402-6
   PubMed Web of Science ®Google Scholar
• Marchetto MC, Carromeu C, Acab A, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010;143:527-39
   PubMed Web of Science ®Google Scholar
• Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 2010;107:15921-6
   PubMed Web of Science ®Google Scholar
• Yazawa M, Dolmetsch RE. Modeling Timothy syndrome with iPS cells. J Cardiovasc Transl Res 2013;6:1-9
   PubMed Web of Science ®Google Scholar
• Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005;115:2025-32
   PubMed Web of Science ®Google Scholar
• Adams CP, Brantner VV. Spending on new drug development. Health Econ 2010;19:130-41
   PubMed Web of Science ®Google Scholar
• Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff 2006;25:420-8
   PubMed Web of Science ®Google Scholar
• Laustriat D, Gide J, Peschanski M. Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem Soc Trans 2010;38:1051-7
   PubMed Web of Science ®Google Scholar
• Sollano JA, Kirsch JM, Bala MV, et al. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Clin Pharmacol Ther 2008;84:263-6
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manage Decis Econ 2007;4-5:469-79
   Google Scholar
• Smith AJ, Nelson NG, Oommen S, et al. Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl Med 2012;1:709-18
   Google Scholar
• Rodriguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32:505-20
   PubMed Web of Science ®Google Scholar
• Takayama K, Kawabata K, Nagamoto Y, et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 2012;34:1781-9
   PubMed Web of Science ®Google Scholar
• Cohen JD, Babiarz JE, Abrams RM, et al. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol Appl Pharmacol 2011;257:74-83
   PubMed Web of Science ®Google Scholar
• Marchetto MC, Winner B, Gage FH. Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. Hum Mol Genet 2010;19:R71-6
   PubMed Web of Science ®Google Scholar
• Yan X, Qin H, Qu C, et al. iPS cells reprogrammed from human mesenchymal-like stem/progenitor cells of dental tissue origin. Stem Cells Dev 2010;19:469-80
   PubMed Web of Science ®Google Scholar
• Tamaoki N, Takahashi K, Tanaka T, et al. Dental pulp cells for induced pluripotent stem cell banking. J Dent Res 2010;89:773-8
   PubMed Web of Science ®Google Scholar
• Rizk A, Rabie BM. Electroporation for transfection and differentiation of dental pulp stem cells. Bioresource Open Access 2013;2:155-62
   Google Scholar
• Arora V, Arora P, Munshi AK. Banking stem cells from human exfoliated deciduous teeth (SHED): saving for the future. J Clin Pediatr Dent 2009;33:289-94
   PubMed Web of Science ®Google Scholar
• Egusa H, Okita K, Kayashima H, et al. Gingival fibroblasts as a promising source of induced pluripotent stem cells. Plos One 2010;5:e12743
   PubMed Web of Science ®Google Scholar
• Wada N, Wang B, Lin NH, et al. Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts. J Periodontal Res 2011;46:438-47
   PubMed Web of Science ®Google Scholar
• Miyoshi K, Tsuji D, Kudoh K, et al. Generation of human induced pluripotent stem cells from oral mucosa. J Biosci Bioeng 2010;110:345-50
   PubMed Web of Science ®Google Scholar
• Rosa V, Della Bona A, Cavalcanti BN, Nor JE. Tissue engineering: from research to dental clinics. Dent Mater 2012;28:341-8
   PubMed Web of Science ®Google Scholar
• Rosa V, Zhang Z, Grande RH, Nor JE. Dental pulp tissue engineering in full-length human root canals. J Dent Res 2013;92:970-5
   PubMed Web of Science ®Google Scholar
• Duan X, Tu Q, Zhang J, et al. Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration. J Cell Physiol 2011;226:150-7
   PubMed Web of Science ®Google Scholar
• Nomura Y, Ishikawa M, Yashiro Y, et al. Human periodontal ligament fibroblasts are the optimal cell source for induced pluripotent stem cells. Histochem Cell Biol 2012;137:719-32
   PubMed Web of Science ®Google Scholar
• Zou XY, Yang HY, Yu Z, et al. Establishment of transgene-free induced pluripotent stem cells reprogrammed from human stem cells of apical papilla for neural differentiation. Stem Cell Res Ther 2012;3:43
   PubMedGoogle Scholar
• Liu L, Liu YF, Zhang J, et al. Ameloblasts serum-free conditioned medium: bone morphogenic protein 4-induced odontogenic differentiation of mouse induced pluripotent stem cells. J Tissue Eng Regen Med 2013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23606575
   Google Scholar
• Srijaya TC, Pradeep PJ, Zain RB, et al. The promise of human induced pluripotent stem cells in dental research. Stem Cells Int 2012;2012:423868
   PubMedGoogle Scholar